Search Results - "Carlsson, G U"

ISO-CC-005; A phase I/II study of arfolitixorin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer by Carlsson, G.U., Guren, T.K., Haux, J., Pfeiffer, P., Taflin, H., Mavroudis, D., Georgoulias, V., Papadimitriou, C., Kentepozidis, N., Boumpas, D., Skintemo, L., Ganlöv, K.M.E., Gustavsson, B.

Get full text

644PIndependent clinical validation of a gene expression profile to predict benefit of 5-FU in metastatic colorectal cancer by Buhl, I K, Carlsson, G U, Saksena, P, Gustavsson, B, Christensen, I J, Edsjö, A, Hansen, A, Knudsen, S, Jensen, P B, Wettergren, Y

“…Abstract Background No biomarkers predict efficacy of 5-FU for metastatic colorectal cancer (mCRC). A gene expression based drug response predictor (DRP) had…”
Get full text

569PISO-CC-005; A phase I/II study of arfolitixorin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer by Carlsson, G U, Guren, T K, Haux, J, Pfeiffer, P, Taflin, H, Mavroudis, D, Georgoulias, V, Papadimitriou, C, Kentepozidis, N, Boumpas, D, Skintemo, L, Ganlöv, K M E, Gustavsson, B

Get full text